St John Donnie McGrath, M.D., MPH
St John Donnie McGrath, M.D., MPH
President and Executive Chairman

St John Donnie McGrath, M.D., MPH

Dr. McGrath has over 22 years of clinical research and pharmaceutical business development experience.

From 2013 to 2017, he was Vice President, Business Development, and Head of Search & Evaluation at Bristol-Myers Squibb, based in Princeton, NJ. During this period, the business development group executed over 50 major transactions in the therapeutic areas of oncology, neuroscience, cardiovascular, fibrosis, 2 immune-science, virology, and genetically-defined diseases. In addition, Dr. McGrath was responsible for overseeing BMS’ venture capital investment portfolio ($350 million), and provided leadership for all global external partnering activities. From 2010 to 2013, he was Executive Director in Business Development responsible for neuroscience and virology business development. In 2005, he joined the BMS virology clinical development group based in Wallingford, CT, as a director of clinical research, and became Group Director in 2007 and the REYATAZ® Development Lead. Dr. McGrath oversaw multiple clinical virology programs resulting in seven major FDA filings for REYATAZ® and SUSTIVA®, and over 60 EMEA procedures submitted and fulfilled.

From 1998 to 2005, he was a physician-researcher in the Division of Geographic Medicine and Infectious Disease at Tufts-New England Medical Center, and an Assistant Professor of Medicine at Tufts Medical School in Boston. From 2002-2004 he was based at the Africa Center for Reproductive Health and Population Studies in KwaZulu Natal, South Africa, where he established an NIH-funded post-graduate training program in medical informatics with the University of KwaZulu Natal School of Medicine and worked on HIV clinical studies.

Dr. McGrath earned his undergraduate degree at University College Dublin, his medical degree from the Royal College of Surgeons in Ireland, and his MPH from the Harvard School of Public Health. He completed his residency in internal medicine at St. Elizabeth’s Medical Center, and fellowship in Infectious Disease at Tufts-New England Medical Center, both in Boston.

Close
Karl Lintel, M.D.
Karl Lintel, M.D.
Chief Executive Officer

Karl Lintel, M.D.

In November 2018, Karl Lintel joined Biohaven to become the COO of its China based subsidiary, Bioshin.

Before that, Karl was the GM for Bristol-Myers Squibb (BMS) China operations since 2014.

Karl got his degree of Medical Doctor from the Gent State University as well as an MBA from the Vlerick School for Management in Belgium.
After having spent two years with UCB in Belgium, he joined in 1992 Pfizer’s Eastern Europe Division as product manager for Anti-Infectives. Later he took the responsibilities of Sales and marketing Director in Poland and of Country manager in Vietnam and in Israel.

In 2000, he became Regional Director for Francophone Africa, based in Morocco, before moving in 2006 to New York as Regional Director for Africa.
In New York HQ, he also assumed responsibility for Global Access allowing him to combine his passion for emerging markets with the challenge of providing health care to those who are underserved by the traditional business models.

In 2010, Karl joined Bristol-Myers Squibb as VP/General manager for Middle East and Africa (MEA), operating from Dubai.

Close
Zoey (Zhiyao) Wang, M.D., MPA
Zoey (Zhiyao) Wang, M.D., MPA
General Manager

Zoey (Zhiyao) Wang, M.D., MPA

Zoey Wang, General Manager, is a physician entrepreneur with over a decade of pharmaceutical experience in China and Europe with Sanofi and Novartis in a variety of clinical operations roles, and is co-founder of MetroHealth, a life science artificial intelligence technology company. She is a board member of BayHelix, a Chinese non-profit professional organization geared to the life sciences and healthcare community.

Zoey is a trained physician with a M.D. degree from Xi’an Jiaotong University, a MPA from Renmin University and was a visiting scholar to UCLA. Zoey is also a guest professor of National University of Singapore (Suzhou) Research Institute.

Close
Elaine Hawkings
Elaine Hawkings
Head of Clinical Operations

Elaine Hawkings

Elaine has over 25 years’ global biopharmaceutical industry experience in international drug development in the area of clinical research. She has consistently delivered results in complex, challenging business environments at country, regional and global levels e.g. record drug approval timelines in Japan and China following regulatory changes.

She is a highly effective cross-cultural communicator and collaborator, who brings global perspectives and insights from working in the UK, France, Belgium, Singapore, Japan, USA, China and Italy.

Elaine was previously Executive Director for Bristol-Myers Squibb, responsible for clinical trials in Asia Pacific from 2009 to 2017 (Japan, China, India, NE Asia, SE Asia and Australia) and a team of ~360 people located in Japan, China, Australia, Korea, Singapore, Taiwan, India and Hong Kong. She led clinical operations for Japan from 2006 to 2009 and from 1996 to 2006 she led clinical operations teams in Europe and Asia.

Elaine is a graduate, with a Bachelor of Science (Hons) degree in Pharmacology from King's College, University of London, holds a Diploma in Clinical Science from the University of Wales and completed the Management Skills for Clinical Researcher curriculum from Vanderbilt University.

Close
Sandy Liang
Sandy Liang
Head of Regulatory Affairs

Sandy Liang

Ms. Liang has over 16 years of drug development experience within Regulatory Affairs. She joined Bioshin after 16 years at MNCs, including Merck, GSK, Abbott China, and a domestic pharmaceutical company, working in the therapeutic areas of fertility, immunology, oncology, endocrine and vaccines. She has a lot of experience in drug registration, including spans all phases of drug development from preclinical research through Phases 3 and marketed products. She and her team get approval of several INDs (NMPA and FDA filing) and NDAs. Ms. Liang earned her B.A. in Shenyang Pharmaceutical University and received a certification of an MBA program in Peking University.

Close
johny Zhang
Jonny Zhang, CPA, CFA
VP Finance

VP Finance

Jonny Zhang has served as Vice President of Finance since December 2020. Jonny brings to BioShin 14 years of finance experience in pharmaceutical, finance and new energy industry. Prior to joining BioShin, Jonny was the Chief Financial Officer of Dataseed Fintech Group, an innovative Fintech platform with asset under management of RMB20 billion (US$3 billion), invested by Sequoia Capital, Focus Media and Sina, from May 2018 to November 2020. Jonny was responsible for developing group financial strategy, digital transformation plan and capital market strategy. Jonny was the Finance Director of SciClone Pharmaceuticals (NASDAQ: SCLN) from November 2015 to December 2017, responsible for financial management for China Operations. From March 2011 to October 2015, Jonny was the senior finance manager of Hanwha Q.CELLS (NASDAQ: HQCL), responsible for group financial reporting and project investment analysis. From July 2007 to February 2011, Jonny worked as senior associate with PricewaterhouseCoopers Zhong Tian LLP.

 

Jonny is a Chartered Financial Analyst and a Certified Public Accountant in U.S. and China. Jonny received his dual Bachelor’s degree of Engineering and Law from Shanghai Jiao Tong University.

Close
Helen Zhang,Master of Clinical Epidemiology
Helen Zhang
Sr.Director Clinical Operations

Sr.Director Clinical Operations

Helen has >16 years of experience in the pharmaceutical industry, and join Bioshin from GSK, where she has worked for >12 years, taking Country Head for China/Hong Kong for the vaccines clinical operational team. As country head, Helen led a team responsible for conducting both local registration trials and phase 4/PMS studies in various therapeutic areas. She has gained significant experience in leading clinical operations teams of CRAs, study managers, vendor management as well as have extensive understanding of HGRAC challenges and experience in developing procedures for her team in China. In GSK she previously held positions as a Clinical Research Manager and as a CRA. Before joining GSK, she worked for Janssen in Medical Affairs as a CRA/TA Physician and for Ruoy Chai International ZhongKe Gene Science Technologies as a medical support Manager. Her first job was at a hospital as a physician in the OB/GY department where she worked for 3 years. She holds a Bachelor’s degree from Bethume Medical University (now Jilin University) and a Master’s degree from China Control and Prevention Disease Center. Helen lives in Beijing.

Close
Matthew Tan,MD
Matthew Tan,MD
VP Medical

VP Medical

Matthew joined Bioshin on Jan 1st, 2021, as VP Medical. He brings to BioShin deep experience in medical affairs and a proven track record of building and leading a highly performing medical team.

Before joining Bioshin, he had been working for Bristol-Myers Squibb for 15 years. From 2014 2017, he was senior director and head of medical, sitting in BMS China operating committee, responsible for medical governance. He led a team of more than 100 people, supervised the development and implementation of medical plan, partnered with HEOR function to support market access, supporting business in the context of compliance. Previously, he was field medical team lead and disease area head of virology medical, while virology has been the main business in BMS China in past ten plus years.

Matthew has experienced several new product launches when he was with BMS, among them, BaracludeTM, an anti-hepatitis B virus product, which was considered a benchmark in China pharma industry. Medical strategy and tactics under his leadership was considered one of the critical success factors.

From 2017 to 2020, he was senior director & tumor strategy lead in BMS China R&D, responsible for immun-oncology clinical development in GI cancers therapeutic area, where he gained experience in the transition from clinical to medical, and new product LCM development.

Close
Chief Strategy Officer, Head of Business Development
David Chung
Chief Strategy Officer, Head of Business Development

David Chung

David has over 20 years of experience working with both biotechnology and top Multi-National Companies. He has global experience, working in Rare/Orphan diseases, Neuroscience, and Oncology therapeutic areas

Before joining BioShin, David was Vice President, Head of Business Development at Intercept Pharmaceuticals, a public US biotech company. Prior to that, David held various senior roles in Strategy, Corporate Development, and Business Development at Bristol Myers Squibb, Jazz Pharmaceuticals, and Johnson & Johnson. He was also a Vice President, Health Care Analyst at Lehman Brothers covering US Major Pharmaceutical companies. The Lehman Brothers US Health Care team was ranked #1 in Institutional Investor‘s All-America Research rankings.

David holds an MBA from the Massachusetts Institute of Technology and a master’s degree from the Johns Hopkins School of Public Health. David is also a Chartered Financial Analyst.

Close
Chief Strategy Officer, Head of Business Development
Sarah (Zhihong) Lu, M.D.,PhD
Chief Medical Officer

Sarah (Zhihong) Lu, M.D.,PhD

Zhihong (Sarah) Lu is a highly seasoned senior pharma executive with extensive both global and  China clinical drug development experience. Sarah joins Bioshin in June 2021 as the CMO. Prior to joining Bioshin, Sarah was the President of Global Development for Shanghai Green Velley.

Sarah has 24 years of clinical development experiences and with various  leadership roles with several MNC and China local companies, such as GSK, UCB, Solvay, Simcere. Sarah has managed large Clinical Development team, including functions such as medical, clinical operation, data management and stats, clinical pharmacology, QA, PV, regulatory etc.

Sarah was trained in both clinical medicine (Neurology) and basic science (pharmacology), studied both in China and US, US board certified physician

Double innovation award granted by Jiangshu Providence in 2019


Close
Chief Strategy Officer, Head of Business Development
Mary Ma
Chief Commercial Officer

Mary Ma

Mary Ma is a seasoned business leader with a proven track record of commercial success spanning over 19 years in the China healthcare market. Mary had held various senior commercial positions in different capacities in Sales, Marketing, Commercial Excellence, & BU with MNC’s such as with GSK, Eli Lilly, Abbvie, and MSD.

Prior to joining BioShin, Mary was the Head of Business Unit, Hospital Specialty Care for MSD China. 

Mary brings a wealth of commercial experience in BU Management, Commercial Excellence, Operations, Specialty Care across various TA’s, Strategic Planning, New Product Launch, Cross-functional Leadership, Change Management, and Innovative Business Models.

Mary graduated in Clinical Medicine at the University of Traditional Chinese Medicine in Shanghai. She is also a certified Lean Six Sigma Black Belt. 


Close